Drug Topics - October 8, 2007 - (Page 52)

DRUG TOPICS 52 New Products STATEMENT OF OWNERSHIP, MANAGEMENT, AND CIRCULATION (Requester Publications Only) 1. 2. 3. 4. 5. 6. 7. (Required by 39 USC 3685) Publication Title: Drug Topics Publication Number: 0012-6616 Filing Date: 9/28/07 Issue Frequency: Semi-monthly except one issue in December Number of Issues Published Annually: 23 Annual Subscription Price (if any): $61.00 Complete Mailing Address of Known Office of Publication: 131 West First Street, Duluth, St. Louis County, Minnesota 55802-2065 Contact Person: Joe Martin Telephone: 218-740-6375 Complete Mailing Address of Headquarters or General Business Office of Publisher: 6200 Canoga Avenue, Woodland Hills, CA 91367. Full Names and Complete Mailing Addresses of Publisher: Joe Laborsky, 123 Tice Blvd., Suite 300, Woodcliff Lake, NJ 07677 Editor In Chief: Judy Chi, 123 Tice Blvd., Suite 300, Woodcliff Lake, NJ 07677 Managing Editor: Daniel Breeman, 123 Tice Blvd., Suite 300, Woodcliff Lake, NJ 07677 This publication is owned by: Advanstar Communications Inc., 6200 Canoga Avenue, Woodland Hills, CA 91367. The sole shareholder of Advanstar Communications Inc. is: Advanstar, Inc., 6200 Canoga Avenue, Woodland Hills, CA 91367. Advanstar Communications Inc. is the Mortgagor under Credit Agreements dated May 31, 2007, with various lenders as named therein from time to time. The agent for the lenders is: Credit Suisse, Administrative Agent, Eleven Madison Avenue, New York, NY 10010. There are no Other Securities as of June, 2007. Does Not Apply Publication Title: Drug Topics Issue Date for Circulation Data Below: August 20, 2007 Extent and Nature of Circulation Average No. Copies Each Issue During Preceding 12 Months A. Total Number of Copies 153,209 B. Legitimate Paid and/or Requested Distribution 1. Individual Paid/Requested Mail Subscriptions Stated on Form 3541 138,727 2. Copies Requested by Employers for Distribution to Employees by Name or Position Stated on Form 3541 9,235 3. Sales Through Dealers and Carriers, Street Vendors, Counter Sales, and Other Paid or Requested Distribution Outside USPS 61 4. Requested Copies Distributed by Other Mail Classes Through the USPS C. Total Paid and/or Requested Circulation (Sum of 15b (1), (2), (3), and (4) 148,023 D. Non-requested Distribution 1. Non-requested Copies as Stated on Form 3541 3,779 2. Non-requested Copies Distributed Through the USPS by Other Classes of Mail 3. Non-requested Copies Distributed Outside the Mail 761 E. Total Non-requested Distribution (Sum of 15d (1), (2), and (3)) 4,540 F. Total Distribution (Sum of 15c and e) 152,563 G. Copies not Distributed 646 H. Total (Sum of 15f and g) 153,209 I. Percent Paid and/or Requested Circulation 97.02% 16. Publication for a Requester Publication is required. Will be printed in the October 8th issue of this publication 17. Name and Title of Editor, Publishers, Business Circulation Director Manager, or Owner: Christine Shappell Signature: Date: I certify that the statements made by me above are correct and complete. No. Copies of Single Issue Published Nearest to Filing Date 157,043 for active immunization against influenza A and B viruses, but only one manufacturer had been licensed in the United States to produce flu vaccine for children under four years of age. NOW AVAILABLE Lipofen (fenofibrate), which was approved last year in 50-, 100-, and 150-mg capsules, was recently licensed from Cipher Pharmaceuticals by ProEthic Pharmaceuticals, Montgomery, Ala., (334) 288-1288. It is now available in pharmacies. Lipofen is approved as adjunctive therapy to diet to reduce elevated LDL, total cholesterol, triglycerides, and Apo B as well as to increase HDL in adult patients with primary hyper-cholesterolemia or mixed dyslipidemia. NEW PACKAGING CYNACON/OCuSOFT Inc., Richmond, Texas, (800) 233-5469, is has a new Alodox Convenience Kit for adjunctive eyelid therapy and hygiene. The kit contains Alodox (doxycycline hyclate 20 mg) to treat inflammation, OCuSOFT Lid Scrub Plus extra-strength premoistened pads, and OCuSOFT Lid Scrub original foaming eyelid cleanser. Sanofi-aventis Group, Bridgewater, N.J., (908) 243-6000, has introduced a new, 200-mg single-use vial of the chemotherapy agent Eloxatin (oxaliplatin injection). The drug had already been available in 50- and 100-mg single-use vials. Eloxatin is indicated for patients with adjuvant stage III colon cancer and advanced colorectal cancer. The new size is expected to provide greater convenience, safety, and flexibility. 8. 9. 10. 11. 12. 13. 14. 15. 146,676 5,740 102 152,518 3,961 153 4,114 156,632 411 157,043 97.37%

Table of Contents Feed for the Digital Edition of Drug Topics - October 8, 2007

Drug Topics - October 8, 2007 Latebreakers Latebreakers in Depth Letters Rx Care Community Practice JP at Large 150 Years of American Pharmacy Hospital Practice Are You Getting Pharmacy's Message Across? Self-Care Government and Law Legal Q&A The Pharmacist as First Responder in Disaster Relief Technology Update New Products Advertisers Index Statement of Ownership Classified Viewpoint

Drug Topics - October 8, 2007

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.